| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
IoT technology is helping companies transform unconnected products into engaging end-user experiences, data-driven insights, and subscription revenue.
Provider of cutting edge evaluation software and source selection software tailored for the Federal Government, by Contracting Officers for Contracting Officers.
Nintex is the global standard for process intelligence and automation. Today more than 10,000 public and private sector organizations across 90 countries turn to the Nintex Process Platform to accelerate progress on their digital transformation journeys by quickly and easily managing, automating and optimizing business processes. Learn more by visiting www.nintex.com and experience how Nintex and its global partner network are shaping the future of Intelligent Process Automation (IPA).
Cxmmunity Media Co. is a media tech company building assets with the mission of future proofing diversity in the esports and video game industry.